Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (113)

III-001Andreas Lindauer

Modeling Copper Kinetics in Wilson’s Disease: A Mechanistic Model to Guide Gene Therapy

Thursday 9:50-11:45

III-002Klaus Lindauer

Application of neural ordinary differential equations (neural-ODE) framework to predict unknown exposure profile in first-in-human (FIH) single ascending trial: comparative analysis with observed data

Thursday 9:50-11:45

III-003Dr Chara Litou

A best practice framework for applying physiologically based pharmacokinetic modelling to predict pH-dependent Drug-Drug Interactions

Thursday 9:50-11:45

III-004Chenyao Liu

Impact of a mobile messaging service on patterns of adherence to antiepileptic medications: a model-based analysis of the SMS Trial

Thursday 9:50-11:45

III-005Feiyan Liu

PBPK Modeling to Recommend Nevirapine Dosing in HIV and HIV-TB Co-infected Patients: Leveraging Enzyme Auto-Induction, Drug Interactions, and Ethnic Variability

Thursday 9:50-11:45

III-006Xuanlin Liu

Mechanistic viral dynamic modeling of in vitro cytomegalovirus infection based on the amount of viral DNA and viral titer

Thursday 9:50-11:45

III-007Ioannis Loisios Konstantinidis

Dose confirmation of asciminib in pediatric patients after oral administration in fasted and low fat fed states using physiologically based pharmacokinetic modeling and simulations

Thursday 9:50-11:45

III-008Aurelie Lombard

Across species translation of a novel liver-targeted GalNAc conjugated siRNA using a minimal PBPK/PD approach

Thursday 9:50-11:45

III-009Doortje Esther Lubberts

Evaluating model-based extrapolation for generic long-acting injectable (LAI) products: from single- to multiple-dose studies

Thursday 9:50-11:45

III-010Frederic Lusoli

Development of a PopPK model to predict the oral absorption of Abemaciclib

Thursday 9:50-11:45

III-011Nicolas Luyckx

Sampling of parameter uncertainty in Campsis

Thursday 9:50-11:45

III-012Katie Lynch

Translational Physiologically Based Pharmacokinetic Modelling of Moxifloxacin for Optimizing Treatment of Tuberculous Meningitis

Thursday 9:50-11:45

III-013Sreenath M Krishnan

A Neural ODE-Based Framework for Modeling Delayed and Multi-Phase Drug Absorption

Thursday 9:50-11:45

III-014Madalena M. A. Peyroteo

Assessing tobemstomig binding dynamics through integrated experimental and computational modeling approaches to inform therapeutic dosing

Thursday 9:50-11:45

III-015Julia Macente

In Vitro-To-In Vivo Extrapolation Of Drug Transfer Into Human Milk Using The Simcyp Simulator: A Contribution From The IMIc4c Conception Project.

Thursday 9:50-11:45

III-016Panos Macheras

Uncovering the true meaning of Cmax and [AUC]0-8: The end of a 72-year-long misconception

Thursday 9:50-11:45

III-017Vincent Madelain

Translational mPBPK-PD modeling to investigate the determinants of human dose prediction for ASO candidates in CNS diseases

Thursday 9:50-11:45

III-018Ruvarashe Joylyne Madzime

Population pharmacokinetics of high-dose isoniazid in children receiving the 3-month weekly rifapentine and isoniazid (3HP) regimen for TB preventive treatment

Thursday 9:50-11:45

III-019Peng Man

Stepwise Covariate Modeling Acceleration Using Individual Uncertainty Adjusted Linear Covariate Screening Methods

Thursday 9:50-11:45

III-020Junjun Mao

A Semi-Mechanistic Model with Glutathione S-transferase Activity to Optimize Busulfan Dosing in Pediatric Hematopoietic Stem Cell Transplantation

Thursday 9:50-11:45

III-021Mathilde Marchand

Operating Characteristics of M-protein Dynamic Metrics to Support Early Decisions in Multiple Myeloma

Thursday 9:50-11:45

III-022John Maringwa

Projecting median survival times for studies with immature survival data to support accelerated approval considerations of treatments in multiple myeloma

Thursday 9:50-11:45

III-023Dr. Lara Marques

Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients

Thursday 9:50-11:45

III-024Frederico Martins

PHYSIOLOGICALLY BASED BIOPHARMACEUTICS MODELING FOR VIRTUAL BIOEQUIVALENCE ASSESSMENT OF METFORMIN IMMEDIATE AND EXTENDED-RELEASE FORMULATIONS

Thursday 9:50-11:45

III-025Camille Massaux

Physiologically based Pharmacokinetic model implementations are different in available Software platforms and their choice can significantly influence the reproduction of results and related Regulatory and clinical decisions: Case of oral contraceptives

Thursday 9:50-11:45

III-026Loes Maton

A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU

Thursday 9:50-11:45

III-027Kazuki Matsuda

Exploring Parameter Estimation When Applying Target-Mediated Drug Disposition Model with Drug Concentration Data Only

Thursday 9:50-11:45

III-028Kevin Mcnally

A meta-model-based workflow for massive efficiency gains when applying global sensitivity analysis to PBPK models

Thursday 9:50-11:45

III-029Francois Mercier

{jmpost}: An R package for Bayesian joint TGI-OS models

Thursday 9:50-11:45

III-030Assil Merlaud

Characterizing the organ-specific association between tumor dynamics and overall survival across cancer types and studies: a Bayesian meta-regression

Thursday 9:50-11:45

III-031Paolo Messina

Leveraging Real-World Data for Osteoarthritis Severity Score Modeling: An InSilicoTrials Platform Application

Thursday 9:50-11:45

III-032Danica Michalickova

Pharmacokinetic optimization of valganciclovir and ganciclovir therapy in lung transplant recipients

Thursday 9:50-11:45

III-033Anna Mikhailova

A Bayesian Workflow for Minimal PBPK Modeling: A Case Study with Dapagliflozin

Thursday 9:50-11:45

III-034Yersultan Mirasbekov

Quantification of tetracosactide (synthetic ACTH) pharmacokinetics and its effects on cortisol production in healthy adults and children

Thursday 9:50-11:45

III-035Anna Mishina

RECORD: software tool for streamlining documentation and enhancing communication of modeling analyses

Thursday 9:50-11:45

III-036Adrien Mitard

Exposure history shapes SARS-CoV-2 viral dynamics in Non-Human Primates and provides insights into correlates of protection against infection and transmission

Thursday 9:50-11:45

III-037Venelin Mitov

MMVSola: An Early PK/PD and Dose Predicting Tool for Antimalarial Drug Development

Thursday 9:50-11:45

III-038Laurynas Mockeliunas

Repeated-time-to-event modelling predicting respiratory tract infections during the COVID-19 pandemic

Thursday 9:50-11:45

III-039Patrick Kofod Mogensen

Understanding the numerical issues in and instability of fits based on the laplace approximation

Thursday 9:50-11:45

III-040Marcel Mohr

Prediction of Drug-Induced Hematotoxicity by an Integrated Clinical-Experimental-Computational Human Hematopoiesis Systems Toxicology Model

Thursday 9:50-11:45

III-041Anaëlle Monfort

Characterization of paroxetine pharmacokinetics during the perinatal period

Thursday 9:50-11:45

III-042Claudio Monteiro

AI-Driven Import of Pharmacometric Models into the Jinko Platform for Enhanced Reusability and Clinical Insight

Thursday 9:50-11:45

III-044Dr BC Narmada

Mechanistic Modeling of Glucagon-Like Peptide (GLP-1) Therapeutics Development for Obesity Management

Thursday 9:50-11:45

III-045Adam Nasim

PKPD Vs AI for Preclinical tumour Xenograft Extrapolation

Thursday 9:50-11:45

III-046Imran Nasim

Towards a Diffusion Based Virtual Subject Generator

Thursday 9:50-11:45

III-047Arnaud Nativel

Prospective validation of an EGFR-Mutated NSCLC mechanistic computational disease model: predicting the combination treatment efficacy of phase III clinical trial

Thursday 9:50-11:45

III-048Nina Nauwelaerts

Enhancing PB(P)K Models for the Female Reproductive Tract: A Framework for Local and Systemic Drug Kinetics

Thursday 9:50-11:45

III-049Bonginkosi Ndzamba

Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV

Thursday 9:50-11:45

III-050Martine Neyens

Interactive shiny application to support design of non-inferiority trials based on surrogate biomarkers.

Thursday 9:50-11:45

III-051Thi Minh Nguyet Nguyen

Informativeness of different in vitro Mycobacterium tuberculosis culture phases in time-kill assay for pharmacokinetic-pharmacodynamic translation

Thursday 9:50-11:45

III-052Van Dong Nguyen

Exploring the impact of clinical covariates on predictive performance of vancomycin population pharmacokinetic modeling in patients receiving high flux intermittent hemodialysis

Thursday 9:50-11:45

III-053Keith Nieforth

ADPO: Automatic-differentiation-assisted parametric optimization algorithm

Thursday 9:50-11:45

III-054Chen Ning

Physiologically Based Pharmacokinetic (PBPK) Modeling of Atorvastatin and Its Three Relevant Metabolites to predict CYP3A4 and OATP1B1-mediated Drug-Drug-Gene Interactions

Thursday 9:50-11:45

III-055Emmanuel Niyigena

A Model-Informed Algorithm for Personalized Infliximab Rescue Therapy to Maximize Colectomy-Free Survival in Patients with Acute Severe Ulcerative Colitis

Thursday 9:50-11:45

III-056Ivan Nicholas Nkuhairwe

Population pharmacokinetics of amikacin in Indian patients with multi-drug-resistant tuberculosis

Thursday 9:50-11:45

III-057Rikard Nordgren

A modified Bayesian information criterion (mBIC) with multiple testing correction for population pharmacokinetic model building

Thursday 9:50-11:45

III-059Eric Novik

A Semi-Mechanistic Longitudinal Gaussian Process Regression Model for Estimating Tumor Response to Treatment

Thursday 9:50-11:45

III-060Enoche Oga

Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of metformin, saxagliptin and dapagliflozin in normal and special patient populations

Thursday 9:50-11:45

III-061Conor O'Hanlon

Pharmacokinetic-Pharmacodynamic informed labelling for Machine Learning classification tasks: predicting severe neutropenia using Real World Data

Thursday 9:50-11:45

III-062Qing Xi Ooi

Population pharmacokinetic-target engagement analysis of ocular and systemic data for intravitreal BI 764524 in patients with diabetic macular ischemia from the HORNBILL study

Thursday 9:50-11:45

III-063Marije Otto

Quantification of subjective effects of esketamine and its metabolite esnorketamine in healthy volunteers using a bounded integer modeling approach

Thursday 9:50-11:45

III-064David Outland

Towards a mechanistic basis of a dynamical vertex model of vascular endothelial cell morphology changes in response to wall shear stress

Thursday 9:50-11:45

III-065Michal Pac

Characterising target organ damage in paediatric patients with primary hypertension: a time-to-event analysis

Thursday 9:50-11:45

III-066Faheemah Padavia

Paracetamol concentrations and time-course of ductus arteriosus diameter in extreme preterm neonates: a population pharmacokinetic-pharmacodynamic analysis

Thursday 9:50-11:45

III-067Seshasai Pallikonda Chakravarthy

QSP Platform Model for Predicting Clinical Efficacy & CRS in CD3xHLA-G T-Cell Engagers (TCEs) for Solid Tumors

Thursday 9:50-11:45

III-068Paulo Paneque Galuzio

Bayesian optimization as an efficient tool for QSP model calibration: a proof-of-concept

Thursday 9:50-11:45

III-069Eirini Panoilia

Pharmacokinetic-target engagement modelling of an anti-CCL17 monoclonal antibody in healthy volunteers and osteoarthritis patients

Thursday 9:50-11:45

III-070Paraskevi Papakyriakopoulou

Semi-Mechanistic Pharmacokinetic Model of Intranasal Fingolimod hydrochloride Administration in Mice

Thursday 9:50-11:45

III-071Caterina Paparsenos

Population Pharmacokinetic and Exposure-Response analyses of Tezepelumab in Phase 3 study (DIRECTION) supports no dose adjustment in Chinese Adults and Adolescents with Asthma.

Thursday 9:50-11:45

III-072Orestis Papatryfonos

Development of a Population PK-PD Model for Tapentadol to Assess Postoperative Pain in Children Aged 6 to <12 using Nonlinear Mixed-Effects Modelling

Thursday 9:50-11:45

III-073Seongwon Park

Meta-based External Validation Through Model Integration Incorporated Prior Information: Application of Tenofovir Alafenamide and Tenofovir

Thursday 9:50-11:45

III-074Suemin Park

Cell-level Pharmacodynamics-Mediated Drug Disposition Model for GI-102 (CD80/IL2v3) in Patients with Advanced or Metastatic Solid Tumors

Thursday 9:50-11:45

III-075Joanna Parkinson

Leading with Excellence: The Impact of Model-Based QT Assessment in Drug Development.

Thursday 9:50-11:45

III-076Zinnia P Parra-Guillen

A population modelling framework to support early clinical development of BI-1910, an agonist monoclonal antibody to tumor necrosis factor 2

Thursday 9:50-11:45

III-077Elena Pascual Garcia

Towards model-informed design of antibiotic therapies: prediction of bacterial physiology & growth in response to ribosome-targeting antibiotics.

Thursday 9:50-11:45

III-078Mark Penney

Predicting the pharmacokinetics of T-Cell Engagers as a function of Target-Mediated Drug Disposition

Thursday 9:50-11:45

III-079Diego Perazzolo

Data-Driven Approach to Covariate Selection in PopPK: Integrating Variational Autoencoders (VAE) and LASSO Regression

Thursday 9:50-11:45

III-080Mariana Pereira

PBPK Modeling of Repurposed HIV Drugs in Prostate Cancer and the Influence of Patient Physiology

Thursday 9:50-11:45

III-081Sara Peribañez-dominguez

Evaluating Metformin Exposure through PBPK Modeling: A Comparative Study between Cancer Patients and Healthy Subjects

Thursday 9:50-11:45

III-082Soumya Perinparajah

Towards Developing a Harmonizing Framework for PK and/or PKPD Scaling for Pain Medications in the Pediatric Population

Thursday 9:50-11:45

III-083Yuan Pétermann

Characterization of rifampicin pharmacokinetics in Tanzanian and South African populations

Thursday 9:50-11:45

III-084Zvonimir Petric

Physiologically Based Pharmacokinetic (PBPK) Modeling of Infliximab: Enhancing Treatment Optimization and Clinical Insights in Inflammatory Bowel Disease (IBD)

Thursday 9:50-11:45

III-085Aleksandr Petrov

In Situ, In Vitro, and In Silico Permeability Values as Inputs for Blood-Brain Barrier Penetration Prediction: Impact on Brain Exposure for Passively Diffusing Compounds, with Ethanol as a Case Study

Thursday 9:50-11:45

III-086Anh Duc Pham

Mechanism-based model of the innate immune response in bacteraemia to assess antibiotic PK/PD targets in immune competent and immune compromised hosts

Thursday 9:50-11:45

III-087Morgane Philipp

From standard to high-dimensional covariate model building: assessing covariate clinical relevance determination using covariate selection approaches (SCM, SCM+) and full modeling methods (FFEM, FREM) in population PK analyses

Thursday 9:50-11:45

III-088Matthias Pierre

Implementation and comparison of six algorithms for automated model building in Monolix: two simulation studies and ten applications

Thursday 9:50-11:45

III-089Veshni Pillay-Fuentes Lorente

Population pharmacokinetics of colistimethate sodium following intravenous administration in critically ill South African adults

Thursday 9:50-11:45

III-090Émilie Pilote

Population Pharmacokinetics of Dolutegravir: A Narrative Review

Thursday 9:50-11:45

III-091Anatoly Pokladyuk

Physiologically-Based Pharmacokinetic Modelling of Niraparib in Special Populations

Thursday 9:50-11:45

III-092Sebastian Polak

Using PBPK-QSP model to move the boundaries of transthyretin stabilization understanding

Thursday 9:50-11:45

III-093Vikram Prabhakar

A Quantitative Systems Pharmacology model to predict clinical Pharmacokinetics/Pharmacodynamics of various small interfering RNA therapeutics and learnings from model development

Thursday 9:50-11:45

III-094Laure-Hélène Préta

Prediction of maternal and fetal exposure to escitalopram, sertraline and paroxetine by combining human ex vivo placenta perfusion data and physiologically-based pharmacokinetic modeling

Thursday 9:50-11:45

III-095Luis Quintairos

Population Pharmacokinetic Modeling and Simulation of Tapentadol Bioequivalence: Assessing the Food Effect

Thursday 9:50-11:45

III-096Ana Quiroga-Campano

Preclinical PK/PD/Efficacy modelling to guide early clinical dose selection for AZD9750, a novel oral Androgen Receptor Proteolysis-targeting chimera (AR-PROTAC)

Thursday 9:50-11:45

III-097Ousama Rachid

Mechanistic Insights in the Ketamine Pharmacokinetics after Intranasal Administration in the Pediatric Population: Bridging Model Validation to Clinical Application

Thursday 9:50-11:45

III-098Najia Rahim

Physiologically based pharmacokinetic modeling of lamotrigine to predict drug disposition using GastroPlusTM

Thursday 9:50-11:45

III-099Anne Ravix

Exploring Bayesian TDM: a simulation-based proof of concept study for vancomycin dosing in virtual neonates

Thursday 9:50-11:45

III-100Alessandro Ravoni

Integrating an Agent-Based Immune Model with PBPK/PKPD to Simulate Antitubercular Treatment in Humans

Thursday 9:50-11:45

III-101Javier Reig-lopez

A Physiologically Based Pharmacokinetic Model of 89Zr-adalimumab in Healthy and Uveitis Diseased Rats

Thursday 9:50-11:45

III-102Elena Righetti

Evaluating a-priori fraction unbound predictions against brain homogenate data: Accounting for the experimental bias

Thursday 9:50-11:45

III-103Francois Riglet

Assessment and development of Machine Learning (ML) methods for covariate model selection in population pharmacokinetics (PopPK) modeling

Thursday 9:50-11:45

III-104Emily Roashan

Population Pharmacokinetic (PK) and mechanistic Pharmacodynamic (PD) model analysis of PHI data for FS222, a CD137/PD-L1 tetravalent, bispecific antibody which elicits robust pharmacodynamic activity in advanced solid tumor patients in a FIH study

Thursday 9:50-11:45

III-105Anne Rodallec

Model-driven scheduling of a novel anti-cancer prodrug administered subcutaneously

Thursday 9:50-11:45

III-106Christelle Rodrigues

Impact of Size-Related Covariates on the Central Volume and Clearance of Monoclonal Antibodies

Thursday 9:50-11:45

III-107Marta Rodríguez

A Phisiological-Based Pharmacokinetic model for CD25 Regulatory T cells targeted nanoparticles

Thursday 9:50-11:45

III-108Maša Roganovic

Association of Adalimumab Clearance with Platelet Levels in Patients with Inflammatory Bowel Disease: A Nonlinear Mixed-Effects Modelling Approach

Thursday 9:50-11:45

III-109Rachel Rose

Applications of an Immunogenicity QSP Platform: Predictive Modelling for ADA and PK Impact for Biotherapeutic Combinations

Thursday 9:50-11:45

III-110Daniel Roeshammar

A prostate cancer QSP framework to explore the efficacy and safety of novel immunotherapies on the InSilicoTrials simulation platform

Thursday 9:50-11:45

III-111M Ruppert

Performance of Neural Ordinary Differential Equations in a multiple dose pharmacometrics setting

Thursday 9:50-11:45

III-112Ine Skottheim Rusten

Operationalizing the ERAMET Digital Research Environment (DRE) – Building the Ecosystem

Thursday 9:50-11:45

III-113Medhat M. Said

Optimizing Imatinib Dosing in Pulmonary Arterial Hypertension: A Repeated Time-to-Event Modeling Approach to Assess Safety

Thursday 9:50-11:45

III-114Anuraag Saini

QSP-Copilot: A GenAI-Powered Multi-Agent System for Accelerating QSP Model Development

Thursday 9:50-11:45

III-115Razan Sakran

Personalizing Busulfan Exposure in Hematopoietic Cell Transplantation

Thursday 9:50-11:45